Current Opinion in Rheumatology

Current Opinion in Rheumatology is a bimonthly review journal published by Lippincott Williams & Wilkins that commissions expert assessments of recent rheumatology literature, established in 1989, with a 2025 Journal Impact Factor of 5.4 and a rank of 7th among 58 rheumatology journals.《风湿病学新观点》（Current Opinion in Rheumatology）由（Lippincott Williams & Wilkins）出版，1989 年创刊，为双月刊综述期刊，约请专家评述风湿病学近期文献，2025 年影响因子为 5.4，在 58 种风湿病学期刊中排名第 7 位。

Scope

• Vasculitis syndromes, including large vessel, medium vessel and small vessel disease, are reviewed.血管炎综合征，包括大血管、中血管与小血管病变。
• Medical physiology as it bears on rheumatic diseases forms a standing section.与风湿病相关的医学生理学设有固定栏目。
• Osteoarthritis and rheumatoid arthritis are covered in dedicated sections.骨关节炎与类风湿关节炎各有专设栏目。
• Crystal deposition diseases, including gout and calcium pyrophosphate deposition, are reviewed.晶体沉积病，包括痛风与焦磷酸钙沉积病。
• Epidemiology and health-related services, including outcomes and health economics, are within scope.流行病学与健康相关服务，含结局研究与卫生经济学。
• The immunopathogenesis and treatment of autoimmune diseases are assessed every year.自身免疫病的免疫发病机制与治疗每年评述一次。
• Clinical therapeutics, spondyloarthropathies, paediatric and heritable disorders, Raynaud phenomenon, scleroderma and myositis are also covered.临床治疗学、脊柱关节炎、儿童与遗传性风湿病、（Raynaud）现象、硬皮病与肌炎亦在范围之内。

History

• Current Opinion in Rheumatology was established in 1989 as a member of the Current Opinion series of review journals.本刊于 1989 年创刊，是（Current Opinion）系列综述期刊的一员。
• Each bimonthly issue covers two or three disciplines, and its reviews assess advances of the previous year rather than report new primary data.每期双月刊聚焦两三个学科，所刊综述评估上一年的进展，而非发表原始数据。
• That structure has proved durable, and the journal reached volume 38 in 2026 while still publishing six issues a year.这一结构延续至今，本刊于 2026 年出至第 38 卷，每年仍出版六期。
• It is published under the Lippincott Williams & Wilkins imprint of Wolters Kluwer, which also hosts the journal on its Ovid platform.本刊以（Wolters Kluwer）旗下（Lippincott Williams & Wilkins）品牌出版，并通过其（Ovid）平台在线发布。
• Its Journal Impact Factor stood at 5.006 in 2021 and 4.941 in 2022, fell to 4.3 in 2024 and recovered to 5.4 in 2025, when it ranked 7th of 58 rheumatology journals.其影响因子 2021 年为 5.006、2022 年为 4.941，2024 年降至 4.3，2025 年回升至 5.4，并在 58 种风湿病学期刊中排名第 7。
• Selected articles are published open access under a Creative Commons Attribution-NonCommercial-NoDerivatives licence, while the journal remains subscription based.部分文章以知识共享署名非商业性禁止演绎许可开放获取，期刊整体仍以订阅为主。

Editors

• The editor is John Varga of the University of Michigan, whose own research concerns scleroderma and fibrosis.主编为密歇根大学的（John Varga），其研究聚焦硬皮病与纤维化。
• An editorial board of sixteen clinicians and scientists represents the United States, Mexico, the Netherlands, Spain, Italy, Canada, Sweden, China, Israel and Japan.由十六位临床医生与科学家组成的编委会来自美国、墨西哥、荷兰、西班牙、意大利、加拿大、瑞典、中国、以色列与日本。
• A dozen subspecialty sections are refreshed once a year, each led by section editors such as Hasan Yazici and Yusuf Yazici for vasculitis and Mirko Manetti for medical physiology.十二个亚专科栏目每年更新一次，分别由（Hasan Yazici）与（Yusuf Yazici）（血管炎）、（Mirko Manetti）（医学生理学）等栏目主编主持。
• Other section editors include Mukundan Attur for osteoarthritis, Kenneth Saag for epidemiology and George Tsokos for immunopathogenesis.其他栏目主编包括负责骨关节炎的（Mukundan Attur）、负责流行病学的（Kenneth Saag）与负责免疫发病机制的（George Tsokos）。
• The journal publishes invited articles only and cannot consider unsolicited manuscripts.本刊仅发表约稿，不受理未经邀请的投稿。
• Each issue combines the commissioned reviews with editorials that frame the key developments.每期将约稿综述与点明关键进展的社论相结合。